Literature DB >> 26166795

The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab.

Zbigniew Bartuzi, Anna Bodzenta-Łukaszyk, Piotr Kuna1, Izabela Kupryś-Lipińska, Ewa Niżankowska-Mogilnicka, Bolesław Samoliński.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26166795     DOI： 10.5603/PiAP.2015.0053

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN： 0867-7077


× No keyword cloud information.
  2 in total

1.  Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma.

Authors:  Krzysztof Pałgan; Magdalena Żbikowska-Götz; Kinga Lis; Elżbieta Chrzaniecka; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2018-07-19       Impact factor: 1.837

2.  Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.

Authors:  Izabela Kupryś-Lipińska; Paweł Majak; Joanna Molinska; Piotr Kuna
Journal:  BMC Pulm Med       Date:  2016-04-26       Impact factor: 3.317
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.